{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T11:00:46Z","timestamp":1776337246116,"version":"3.51.2"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40264-025-01639-1","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T10:24:54Z","timestamp":1764930294000},"page":"553-565","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unsuspected Adverse Drug Reactions to Dermatologic Medications: An Epidemiological Hypothesis-Free Screening Study of Real-World Data in Denmark"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7224-7833","authenticated-orcid":false,"given":"Thomas","family":"Delvin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anette","family":"Bygum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars Christian","family":"Lund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob Harbo","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesper","family":"Hallas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"1639_CR1","unstructured":"Global burden of preventable medication-related harm in health care: a systematic review. 1st ed. Geneva: World Health Organization; 2024."},{"key":"1639_CR2","doi-asserted-by":"crossref","unstructured":"Hazell L, Shakir SAW. Under-reporting of adverse drug reactions. Drug Safety. 2006;12:385\u201396.","DOI":"10.2165\/00002018-200629050-00003"},{"key":"1639_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/DHPS.S205119","volume":"11","author":"JEL Cornwall","year":"2019","unstructured":"Cornwall JEL, Bygum A, Rasmussen ER. ACE-inhibitor related angioedema is not sufficiently reported to the Danish Adverse Drug Reactions Database. DHPS. 2019;11:105\u201313. https:\/\/doi.org\/10.2147\/DHPS.S205119.","journal-title":"DHPS"},{"key":"1639_CR4","doi-asserted-by":"publisher","first-page":"204209861986474","DOI":"10.1177\/2042098619864744","volume":"10","author":"A Bate","year":"2019","unstructured":"Bate A, Hornbuckle K, Juhaeri J, Motsko SP, Reynolds RF. Hypothesis-free signal detection in healthcare databases: finding its value for pharmacovigilance. Ther Adv Drug Saf. 2019;10:2042098619864744. https:\/\/doi.org\/10.1177\/2042098619864744.","journal-title":"Ther Adv Drug Saf"},{"key":"1639_CR5","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1002\/cpt.2172","volume":"109","author":"A Lavertu","year":"2021","unstructured":"Lavertu A, Vora B, Giacomini KM, Altman R, Rensi S. A new era in pharmacovigilance: toward real-world data and digital monitoring. Clin Pharma Therapeutics. 2021;109:1197\u2013202. https:\/\/doi.org\/10.1002\/cpt.2172.","journal-title":"Clin Pharma Therapeutics."},{"key":"1639_CR6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s10654-018-0386-8","volume":"33","author":"J Hallas","year":"2018","unstructured":"Hallas J, Wang SV, Gagne JJ, Schneeweiss S, Pratt N, Potteg\u00e5rd A. Hypothesis-free screening of large administrative databases for unsuspected drug-outcome associations. Eur J Epidemiol. 2018;33:545\u201355. https:\/\/doi.org\/10.1007\/s10654-018-0386-8.","journal-title":"Eur J Epidemiol"},{"key":"1639_CR7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jamadermatol.2020.4968","volume":"157","author":"A Egeberg","year":"2021","unstructured":"Egeberg A, Schwarz P, Harsl\u00f8f T, Andersen YMF, Potteg\u00e5rd A, Hallas J, et al. Association of potent and very potent topical corticosteroids and the risk of osteoporosis and major osteoporotic fractures. JAMA Dermatol. 2021;157:275\u201382. https:\/\/doi.org\/10.1001\/jamadermatol.2020.4968.","journal-title":"JAMA Dermatol"},{"key":"1639_CR8","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.2337\/dc18-2158","volume":"42","author":"YMF Andersen","year":"2019","unstructured":"Andersen YMF, Egeberg A, Ban L, Gran S, Williams HC, Francis NA, et al. Association between topical corticosteroid use and type 2 diabetes in two European population-based adult cohorts. Diabetes Care. 2019;42:1095\u2013103. https:\/\/doi.org\/10.2337\/dc18-2158.","journal-title":"Diabetes Care"},{"key":"1639_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70071","volume":"34","author":"SH Bots","year":"2025","unstructured":"Bots SH, Brown J, Wong AYS, Martin I, Douglas I, Klungel OH, et al. Core concepts: self-controlled designs in pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2025;34:e70071. https:\/\/doi.org\/10.1002\/pds.70071.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1639_CR10","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/ije\/dyw213","volume":"46","author":"A Potteg\u00e5rd","year":"2017","unstructured":"Potteg\u00e5rd A, Schmidt SAJ, Wallach-Kildemoes H, S\u00f8rensen HT, Hallas J, Schmidt M. Data resource profile: The Danish National Prescription Registry. Int J Epidemiol. 2017;46:798\u2013798f. https:\/\/doi.org\/10.1093\/ije\/dyw213.","journal-title":"Int J Epidemiol"},{"key":"1639_CR11","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S91125","author":"M Schmidt","year":"2015","unstructured":"Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, S\u00f8rensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. CLEP. 2015. https:\/\/doi.org\/10.2147\/CLEP.S91125.","journal-title":"CLEP"},{"key":"1639_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1177\/1403494810394718","volume":"39","author":"JS Andersen","year":"2011","unstructured":"Andersen JS, Olivarius NDF, Krasnik A. The Danish National Health Service Register. Scand J Public Health. 2011;39:34\u20137. https:\/\/doi.org\/10.1177\/1403494810394718.","journal-title":"Scand J Public Health"},{"key":"1639_CR13","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","volume":"29","author":"M Schmidt","year":"2014","unstructured":"Schmidt M, Pedersen L, S\u00f8rensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29:541\u20139. https:\/\/doi.org\/10.1007\/s10654-014-9930-3.","journal-title":"Eur J Epidemiol"},{"key":"1639_CR14","unstructured":"Home. https:\/\/english.sundhedsdatastyrelsen.dk\/. Accessed 31 Mar 2025"},{"key":"1639_CR15","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10654-017-0281-8","volume":"32","author":"EC-C Lai","year":"2017","unstructured":"Lai EC-C, Pratt N, Hsieh C-Y, Lin S-J, Potteg\u00e5rd A, Roughead EE, et al. Sequence symmetry analysis in pharmacovigilance and pharmacoepidemiologic studies. Eur J Epidemiol. 2017;32:567\u201382. https:\/\/doi.org\/10.1007\/s10654-017-0281-8.","journal-title":"Eur J Epidemiol"},{"key":"1639_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5774","volume":"33","author":"T Delvin","year":"2024","unstructured":"Delvin T, Egsgaard S, Hallas J, Kildegaard H, Lund LC, Rahbek MT. Is the sequence ratio an unbiased estimate of the incidence rate ratio? A simulation study. Pharmacoepidemiol Drug Saf. 2024;33:e5774. https:\/\/doi.org\/10.1002\/pds.5774.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1639_CR17","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/joim.12186","volume":"275","author":"J Hallas","year":"2014","unstructured":"Hallas J, Potteg\u00e5rd A. Use of self-controlled designs in pharmacoepidemiology. J Intern Med. 2014;275:581\u20139. https:\/\/doi.org\/10.1111\/joim.12186.","journal-title":"J Intern Med"},{"key":"1639_CR18","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.1736","volume":"18","author":"I Tsiropoulos","year":"2009","unstructured":"Tsiropoulos I, Andersen M, Hallas J. Adverse events with use of antiepileptic drugs: a prescription and event symmetry analysis. Pharmacoepidemiol Drug Saf. 2009;18:483\u201391. https:\/\/doi.org\/10.1002\/pds.1736.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1639_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-199609000-00005","author":"J Hallas","year":"1996","unstructured":"Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology. 1996. https:\/\/doi.org\/10.1097\/00001648-199609000-00005.","journal-title":"Epidemiology"},{"key":"1639_CR20","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/pds.3417","volume":"22","author":"IA Wahab","year":"2013","unstructured":"Wahab IA, Pratt NL, Wiese MD, Kalisch LM, Roughead EE. The validity of sequence symmetry analysis (SSA) for adverse drug reaction signal detection: SSA FOR ADVERSE DRUG REACTION DETECTION. Pharmacoepidemiol Drug Saf. 2013;22:496\u2013502. https:\/\/doi.org\/10.1002\/pds.3417.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1639_CR21","volume":"70","author":"ST S\u00f8rensen","year":"2023","unstructured":"S\u00f8rensen ST, Kristensen FP, Troelsen FS, Schmidt M, S\u00f8rensen HT. Health registries as research tools: a review of methodological key issues. Dan Med J. 2023;70:A12220796.","journal-title":"Dan Med J"},{"key":"1639_CR22","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/pds.5578","volume":"32","author":"LC Lund","year":"2023","unstructured":"Lund LC, Hallas J. Recommendations on the calculation of confidence intervals for sequence symmetry analyses. Pharmacoepidemiol Drug Saf. 2023;32:392\u20134. https:\/\/doi.org\/10.1002\/pds.5578.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1639_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5723","volume":"33","author":"MT Rahbek","year":"2024","unstructured":"Rahbek MT, Hallas J, Lund LC. Trend adjustment of the sequence difference when performing sequence symmetry analyses. Pharmacoepidemiol Drug Saf. 2024;33:e5723. https:\/\/doi.org\/10.1002\/pds.5723.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1639_CR24","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/oxfordjournals.aje.a115853","volume":"133","author":"M Maclure","year":"1991","unstructured":"Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991;133:144\u201353.","journal-title":"Am J Epidemiol"},{"key":"1639_CR25","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/00001648-199605000-00003","volume":"7","author":"S Greenland","year":"1996","unstructured":"Greenland S. Confounding and exposure trends in case-crossover and case-time-control designs. Epidemiology. 1996;7:231\u20139. https:\/\/doi.org\/10.1097\/00001648-199605000-00003.","journal-title":"Epidemiology"},{"key":"1639_CR26","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/aje\/kww079","volume":"184","author":"J Hallas","year":"2016","unstructured":"Hallas J, Potteg\u00e5rd A, Wang S, Schneeweiss S, Gagne JJ. Persistent user bias in case-crossover studies in pharmacoepidemiology. Am J Epidemiol. 2016;184:761\u20139. https:\/\/doi.org\/10.1093\/aje\/kww079.","journal-title":"Am J Epidemiol"},{"key":"1639_CR27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/1403494811399956","volume":"39","author":"LC Thygesen","year":"2011","unstructured":"Thygesen LC, Daasnes C, Thaulow I, Br\u00f8nnum-Hansen H. Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation, and archiving. Scand J Public Health. 2011;39:12\u20136. https:\/\/doi.org\/10.1177\/1403494811399956.","journal-title":"Scand J Public Health"},{"key":"1639_CR28","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1303a133","volume":"13","author":"H Aktas","year":"2023","unstructured":"Aktas H, Bah\u00e7e Z\u015e. Evaluation of the incidence of anal fissures in patients who systemic isotretinoin therapy for acne. Dermatol Pract Concept. 2023;13:e2023133. https:\/\/doi.org\/10.5826\/dpc.1303a133.","journal-title":"Dermatol Pract Concept"},{"key":"1639_CR29","doi-asserted-by":"publisher","first-page":"970","DOI":"10.5455\/medscience.2020.07.141","volume":"9","author":"P Basim","year":"2020","unstructured":"Basim P, Yuksel M. A common but not well-known cause in anal fissure development and treatment failure: isotretinoin treatment for acne vulgaris. Med-Science. 2020;9:970. https:\/\/doi.org\/10.5455\/medscience.2020.07.141.","journal-title":"Med-Science."},{"key":"1639_CR30","doi-asserted-by":"publisher","first-page":"6085","DOI":"10.3390\/ijms20236085","volume":"20","author":"S Morgan","year":"2019","unstructured":"Morgan S, Hooper KM, Milne EM, Farquharson C, Stevens C, Staines KA. Azathioprine has a deleterious effect on the bone health of mice with DSS-induced inflammatory bowel disease. IJMS. 2019;20:6085. https:\/\/doi.org\/10.3390\/ijms20236085.","journal-title":"IJMS."},{"key":"1639_CR31","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/jbmr.5650100119","volume":"10","author":"HP Bryer","year":"1995","unstructured":"Bryer HP, Isserow JA, Armstrong EC, Mann GN, Rucinski B, Buchinsky FJ, et al. AzaThioprine alone is bone sparing and does not alter cyclosporin A-induced osteopenia in the rat. J Bone Miner Res. 1995;10:132\u20138. https:\/\/doi.org\/10.1002\/jbmr.5650100119.","journal-title":"J Bone Miner Res"},{"key":"1639_CR32","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1046\/j.1365-2796.1998.00246.x","volume":"243","author":"CH Flor\u00e9n","year":"1998","unstructured":"Flor\u00e9n CH, Ahr\u00e9n B, Bengtsson M, Bartosik J, Obrant K. Bone mineral density in patients with Crohn\u2019s disease during long-term treatment with azathioprine. J Intern Med. 1998;243:123\u20136. https:\/\/doi.org\/10.1046\/j.1365-2796.1998.00246.x.","journal-title":"J Intern Med"},{"key":"1639_CR33","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrmicro.2017.157","volume":"16","author":"AL Byrd","year":"2018","unstructured":"Byrd AL, Belkaid Y, Segre JA. The human skin microbiome. Nat Rev Microbiol. 2018;16:143\u201355. https:\/\/doi.org\/10.1038\/nrmicro.2017.157.","journal-title":"Nat Rev Microbiol"},{"key":"1639_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2023.114764","volume":"458","author":"AJ Sales","year":"2024","unstructured":"Sales AJ, Joca SRL, Del Bel E, Guimar\u00e3es FS. The antidepressant-like effect of doxycycline is associated with decreased nitric oxide metabolite levels in the prefrontal cortex. Behav Brain Res. 2024;458:114764. https:\/\/doi.org\/10.1016\/j.bbr.2023.114764.","journal-title":"Behav Brain Res"},{"key":"1639_CR35","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.bbi.2023.12.036","volume":"117","author":"LD de Witte","year":"2024","unstructured":"de Witte LD, Munk Laursen T, Corcoran CM, Munk-Olsen T, Bergink V. Association between doxycycline use and long-term functioning in patients with schizophrenia. Brain Behav Immun. 2024;117:66\u20139. https:\/\/doi.org\/10.1016\/j.bbi.2023.12.036.","journal-title":"Brain Behav Immun"},{"key":"1639_CR36","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.79671","author":"ECN Lim","year":"2025","unstructured":"Lim ECN, Cheng NCL, Lim CED. Beyond infection: a case of doxycycline-induced mania and prolonged neuropsychiatric disturbance. Cureus. 2025. https:\/\/doi.org\/10.7759\/cureus.79671.","journal-title":"Cureus."},{"key":"1639_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2020.100148","volume":"9","author":"N Essali","year":"2020","unstructured":"Essali N, Miller BJ. Psychosis as an adverse effect of antibiotics. Brain Behav Immun Health. 2020;9:100148. https:\/\/doi.org\/10.1016\/j.bbih.2020.100148.","journal-title":"Brain Behav Immun Health"},{"key":"1639_CR38","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/archinte.166.9.1016","volume":"166","author":"CS van der Hooft","year":"2006","unstructured":"van der Hooft CS, Heeringa J, Brusselle GG, Hofman A, Witteman JCM, Kingma JH, et al. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med. 2006;166:1016\u201320. https:\/\/doi.org\/10.1001\/archinte.166.9.1016.","journal-title":"Arch Intern Med"},{"key":"1639_CR39","doi-asserted-by":"publisher","DOI":"10.1161\/circ.144.suppl_1.13683","volume":"144","author":"Y Lee","year":"2021","unstructured":"Lee Y, Jehangir Q, Poisson L, Latack K, Krishnamoorthy G, Sule A, et al. Abstract 13683: corticosteroids and the risk of atrial fibrillation in hospitalized COVID-19 patients. Circulation. 2021;144:A13683. https:\/\/doi.org\/10.1161\/circ.144.suppl_1.13683. (American Heart Association).","journal-title":"Circulation"},{"key":"1639_CR40","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1093\/rheumatology\/41.7.741","volume":"41","author":"NJ Minaur","year":"2002","unstructured":"Minaur NJ, Kounali D, Vedi S, Compston JE, Beresford JN, Bhalla AK. Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. Rheumatology. 2002;41:741\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/41.7.741.","journal-title":"Rheumatology"},{"key":"1639_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-002982","volume":"9","author":"D Singh","year":"2023","unstructured":"Singh D, Hesse N, Skapenko A, Schulze-Koops H. A rare side effect of methotrexate therapy: drug-induced osteopathy with multiple fractures of the lower limb. RMD Open. 2023;9:e002982. https:\/\/doi.org\/10.1136\/rmdopen-2023-002982.","journal-title":"RMD Open"},{"key":"1639_CR42","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1136\/annrheumdis-2024-eular.4575","volume":"83","author":"B Hauser","year":"2024","unstructured":"Hauser B, Merriman A, Foley J, Golla J, Mcrorie E. Op0090 continuous treatment with methotrexate leads to increased overall fracture rate in patients who sustained methotrexate associated lower limb insufficiency fractures. Ann Rheumatic Dis. 2024;83:147\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2024-eular.4575. (BMJ Publishing Group Ltd).","journal-title":"Ann Rheumatic Dis."},{"key":"1639_CR43","doi-asserted-by":"crossref","unstructured":"Mazanec DJ, Grisanti JM. Drug-induced osteoporosis. 1989;56.","DOI":"10.3949\/ccjm.56.3.297"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01639-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-025-01639-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01639-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T10:15:13Z","timestamp":1776334513000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-025-01639-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1639"],"URL":"https:\/\/doi.org\/10.1007\/s40264-025-01639-1","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Thomas Delvin reports being an employee of LEO Pharma A\/S. Anette Bygum reports involvement in research and educational activities with Takeda, CSL Behring, Biocryst, Eli Lilly, Pierre Fabre, and Sanofi. Lars Christian Lund reports participation in research projects funded by Menarini Pharmaceuticals and LEO Pharma; all funds were paid to the institution where he was employed (no personal fees), and these projects had no relation to the current work. Jacob Harbo Andersen reports no conflicts of interest. Jesper Hallas reports participation in research projects funded by Alcon, Almirall, Astellas, Astra-Zeneca, Boehringer-Ingelheim, Novo Nordisk, Servier, and LEO Pharma; all funds were paid to the institution where he was employed (no personal fees), and these projects had no relation to the current proposal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"According to Danish law, studies based entirely on registry data do not require approval from an ethics review board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Data were accessed and analyzed within the data environment provided by the Danish Health Data Authority.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable. This study was based entirely on anonymized national registry data, for which individual patient consent is not required under Danish law.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data were accessed and analyzed within the secure data environment provided by the Danish Health Data Authority. Due to Danish data protection regulations protecting patient privacy, raw data cannot be made publicly available or shared. Access to the underlying data can be granted to eligible researchers upon successful application to the Danish Health Data Authority.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors made substantial contributions to the conception or design of the work, or the acquisition, analysis, or interpretation of data for the work; drafted the work or reviewed it critically for important intellectual content; gave final approval of the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. JH Andersen, T Delvin, and J Hallas had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. The authors report the use of Google's Gemini (version 2.5 PRO) on several occasions between April 15, 2025, and May 25, 2025, to assist with linguistic fine-tuning and language polishing of the manuscript. The authors take full responsibility for the integrity of the content generated and all final wording.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' Contributions"}},{"value":"The protocol was pre-registered at the Real-World Evidence Registry and the Open Science Framework before final analysis (\n                      \n                      ).","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Protocol Registration"}}]}}